Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 101

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis44Glioblastoma41Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Partial seizures19Cognitive disorder18Epilepsy18Giant cell arteritis18Anaesthesia17Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+435

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Metachromatic leukodystrophy

Not recruiting

Study of Atidarsagene Autotemcel for Treating Early Onset Metachromatic Leukodystrophy (MLD) in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited

Parkinson's disease

Not recruiting

Study on the Effectiveness and Safety of ND0612 Infusion vs. Oral Treatment for Parkinson's Disease Patients with Motor Fluctuations

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carbidopa
  • Sponsor:Neuroderm Ltd.

Huntington's disease

Not recruiting

Study on the Safety and Efficacy of Tominersen for Patients with Prodromal and Early Manifest Huntington's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Tominersen
  • Sponsor:F. Hoffmann-La Roche AG

Neurofibromatosis+1

Not recruiting

Study on Selumetinib for Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Selumetinib
  • Sponsor:AstraZeneca AB

Obstructive sleep apnoea syndrome

Not recruiting

Study of Nacystelyn for Patients with Obstructive Sleep Apnea

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nacystelyn
  • Sponsor:Laboratoires S.M.B.

Petit mal epilepsy+1

Not recruiting

Study of brivaracetam as a treatment for childhood and juvenile absence epilepsy in patients aged 2-25 years

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Brivaracetam
  • Sponsor:UCB Biopharma

Ischaemic stroke

Not recruiting

Study on Glenzocimab for Patients with Large Ischemic Stroke Eligible for Endovascular Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Gadobutrol
  • Sponsor:Fondation A De Rothschild

Seizure+1

Not recruiting

Study on the Effects of Psilocybin for Patients with Psychogenic Non-Epileptic Seizures (PNES)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Psilocybine
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Metastases to central nervous system+1

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with HER2-Low Breast Cancer and New or Worsening Brain Metastases

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Medica Scientia Innovation Research S.L.

Cognitive disorder+1

Not recruiting

Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid
  • Sponsor:Recognify Life Sciences Inc.

Facial paresis

Not recruiting

Study on Betamethasone Sodium Phosphate for Treating Acute Facial Nerve Palsy in Children

Registered drug
Countries:SwedenSweden
  • Participants:0–17 years
  • Sponsor:Region Dalarna

Alexander disease

Not recruiting

Study of ION373 Given by Spinal Injection for Patients with Alexander Disease

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:2'-O-(2-Methoxyethyl)-D-Ribose Antisense Oligonucleotide Targeting Glial Fibrillary Acidic Protein Messenger Ribonucleic Acid
  • Sponsor:Ionis Pharmaceuticals Inc.

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride71 clinical trialsTemozolomide38 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide24 clinical trialsParacetamol24 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trialsCarboplatin14 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.